Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,525 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease.
González-Naranjo P, Pérez-Macias N, Campillo NE, Pérez C, Arán VJ, Girón R, Sánchez-Robles E, Martín MI, Gómez-Cañas M, García-Arencibia M, Fernández-Ruiz J, Páez JA. González-Naranjo P, et al. Among authors: perez macias n, perez c. Eur J Med Chem. 2014 Feb 12;73:56-72. doi: 10.1016/j.ejmech.2013.11.026. Epub 2013 Dec 7. Eur J Med Chem. 2014. PMID: 24378710
Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors.
Chierrito TPC, Pedersoli-Mantoani S, Roca C, Sebastian-Pérez V, Martínez-Gonzalez L, Pérez DI, Perez C, Canales A, Cañada FJ, Campillo NE, Carvalho I, Martinez A. Chierrito TPC, et al. Among authors: perez di, perez c. Eur J Med Chem. 2018 Feb 10;145:431-444. doi: 10.1016/j.ejmech.2018.01.007. Epub 2018 Jan 5. Eur J Med Chem. 2018. PMID: 29335209
Multitarget drugs as potential therapeutic agents for alzheimer's disease. A new family of 5-substituted indazole derivatives as cholinergic and BACE1 inhibitors.
González-Naranjo P, Pérez C, González-Sánchez M, Gironda-Martínez A, Ulzurrun E, Bartolomé F, Rubio-Fernández M, Martin-Requero A, Campillo NE, Páez JA. González-Naranjo P, et al. Among authors: perez c. J Enzyme Inhib Med Chem. 2022 Dec;37(1):2348-2356. doi: 10.1080/14756366.2022.2117315. J Enzyme Inhib Med Chem. 2022. PMID: 36050834 Free PMC article.
Indazolylketones as new multitarget cannabinoid drugs.
González-Naranjo P, Pérez-Macias N, Pérez C, Roca C, Vaca G, Girón R, Sánchez-Robles E, Martín-Fontelles MI, de Ceballos ML, Martin-Requero A, Campillo NE, Páez JA. González-Naranjo P, et al. Among authors: perez macias n, perez c. Eur J Med Chem. 2019 Mar 15;166:90-107. doi: 10.1016/j.ejmech.2019.01.030. Epub 2019 Jan 17. Eur J Med Chem. 2019. PMID: 30685536
New cannabinoid receptor antagonists as pharmacological tool.
González-Naranjo P, Pérez C, Girón R, Sánchez-Robles EM, Martín-Fontelles MI, Carrillo-López N, Martín-Vírgala J, Naves M, Campillo NE, Páez JA. González-Naranjo P, et al. Among authors: perez c. Bioorg Med Chem. 2020 Oct 1;28(19):115672. doi: 10.1016/j.bmc.2020.115672. Epub 2020 Jul 29. Bioorg Med Chem. 2020. PMID: 32912440
Tacrine-melatonin hybrids as multifunctional agents for Alzheimer's disease, with cholinergic, antioxidant, and neuroprotective properties.
Fernández-Bachiller MI, Pérez C, Campillo NE, Páez JA, González-Muñoz GC, Usán P, García-Palomero E, López MG, Villarroya M, García AG, Martínez A, Rodríguez-Franco MI. Fernández-Bachiller MI, et al. Among authors: perez c. ChemMedChem. 2009 May;4(5):828-41. doi: 10.1002/cmdc.200800414. ChemMedChem. 2009. PMID: 19308922
3,525 results